Cargando…

Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients

INTRODUCTION: ambrisentan and phosphodiesterase type 5 inhibitor (PDE5i) have been approved for treating patients with pulmonary arterial hypertension (PAH). Echocardiographic right ventricular pulmonary artery coupling (RVPAC) has been shown to be a valid non-invasive and alternative measurement me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lan, Wei-Fang, Deng, Yan, Wei, Bin, Huang, Kai, Dai, Ping, Xie, Shan-Shan, Wu, Dan-dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113403/ https://www.ncbi.nlm.nih.gov/pubmed/35592406 http://dx.doi.org/10.3389/fcvm.2022.843606

Ejemplares similares

Ambrisentan for the treatment of pulmonary arterial hypertension
por: Casserly, Brian, et al.
Publicado: (2009)

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
por: Li, Jie, et al.
Publicado: (2022)

A review of pulmonary arterial hypertension: role of ambrisentan
por: Barst, Robyn J
Publicado: (2007)

Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
por: Elshaboury, Soha M, et al.
Publicado: (2013)

Echocardiographic Assessment of Right Ventricular–Arterial Coupling in Predicting Prognosis of Pulmonary Arterial Hypertension Patients
por: Kazimierczyk, Remigiusz, et al.
Publicado: (2021)

Echocardiographic Prognosis Relevance of Attenuated Right Heart Remodeling in Idiopathic Pulmonary Arterial Hypertension
por: Zhao, Qin-Hua, et al.
Publicado: (2021)

Right Ventricular Function and Its Coupling With Pulmonary Circulation in Precapillary Pulmonary Hypertension: A Three-Dimensional Echocardiographic Study
por: Li, Yidan, et al.
Publicado: (2021)

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension
por: Safdar, Zeenat
Publicado: (2011)

Right ventricular-pulmonary arterial coupling impairment and exercise capacity in obese adults
por: Zhou, Na, et al.
Publicado: (2022)

Right Ventricle to Pulmonary Artery Coupling Predicts the Risk Stratification in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
por: Lai, Jinzhi, et al.
Publicado: (2022)

Echocardiographic evaluations of right ventriculo–arterial coupling in experimental and clinical pulmonary hypertension
por: Boulate, David, et al.
Publicado: (2019)

Echocardiographic, Biochemical, and Electrocardiographic Correlates Associated With Progressive Pulmonary Arterial Hypertension
por: Zaky, Ahmed, et al.
Publicado: (2021)

Evaluation of right ventricular function in patients with pulmonary arterial hypertension by different right ventricular-pulmonary artery coupling methods
por: Dong, Yaling, et al.
Publicado: (2022)

17β-estradiol preserves right ventricular function in rats with pulmonary arterial hypertension: an echocardiographic and histochemical study
por: Wang, Yi-Dan, et al.
Publicado: (2018)

Corrigendum: Right ventricular-pulmonary arterial coupling impairment and exercise capacity in obese adults
por: Na, Zhou, et al.
Publicado: (2022)

Correlation between right ventricular–pulmonary artery coupling and the prognosis of patients with pulmonary arterial hypertension
por: Nie, Lin, et al.
Publicado: (2019)

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Gong, Su-Gang, et al.
Publicado: (2018)

Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment
por: Alandejani, Faisal, et al.
Publicado: (2022)

Pulmonary Arterial Remodeling Is Related to the Risk Stratification and Right Ventricular-Pulmonary Arterial Coupling in Patients With Pulmonary Arterial Hypertension
por: Grignola, Juan C., et al.
Publicado: (2021)

Right Ventricular Diastolic Performance in Patients With Chronic Thromboembolic Pulmonary Hypertension Assessed by Echocardiography
por: Meng, Hong, et al.
Publicado: (2021)

When right ventricular pressure meets volume: The impact of arrival time of reflected waves on right ventricle load in pulmonary arterial hypertension
por: Fukumitsu, Masafumi, et al.
Publicado: (2022)

Acetazolamide Improves Right Ventricular Function and Metabolic Gene Dysregulation in Experimental Pulmonary Arterial Hypertension
por: Spyropoulos, Fotios, et al.
Publicado: (2021)

Glyoxylase-1 combats dicarbonyl stress and right ventricular dysfunction in rodent pulmonary arterial hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2022)

Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Chen, Jingyuan, et al.
Publicado: (2021)

Echocardiographic assessment of right ventricular function in experimental pulmonary hypertension
por: Zhu, Zhongkai, et al.
Publicado: (2019)

Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice
por: Kataoka, Masaharu, et al.
Publicado: (2019)

Prognostic value of three-dimensional echocardiographic right ventricular ejection fraction in patients with pulmonary arterial hypertension
por: Murata, Mitsushige, et al.
Publicado: (2016)

Multi‐Beat Right Ventricular‐Arterial Coupling Predicts Clinical Worsening in Pulmonary Arterial Hypertension
por: Hsu, Steven, et al.
Publicado: (2020)

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Echocardiographic evaluation of right ventricular diastolic function in pulmonary hypertension
por: Yogeswaran, Athiththan, et al.
Publicado: (2023)

Relaxin Inhibits Ventricular Arrhythmia and Asystole in Rats With Pulmonary Arterial Hypertension
por: Martin, Brian, et al.
Publicado: (2021)

Clinical significance of right ventricular–pulmonary arterial coupling in patients with tricuspid regurgitation before closure of atrial septal defect
por: Lee, Seon Hwa, et al.
Publicado: (2022)

Normal Echocardiographic Reference Values of the Right Ventricular to Left Ventricular Endsystolic Diameter Ratio and the Left Ventricular Endsystolic Eccentricity Index in Healthy Children and in Children With Pulmonary Hypertension
por: Schweintzger, Sabrina, et al.
Publicado: (2022)

Effect of systemic hypertension on right ventricular morphology and function: an echocardiographic study
por: Akintunde, AA, et al.
Publicado: (2010)

Open label study of ambrisentan in patients with exercise pulmonary hypertension
por: Segrera, Sergio A., et al.
Publicado: (2017)

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
por: Escribano-Subias, Pilar, et al.
Publicado: (2019)

Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition
por: Cavasin, Maria A, et al.
Publicado: (2014)

Pulmonary artery diameter correlates with echocardiographic parameters of right ventricular dysfunction in patients with acute pulmonary embolism
por: O’Corragain, Oisin, et al.
Publicado: (2023)

Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Diagnostic Value of Right Pulmonary Artery Distensibility Index in Dogs with Pulmonary Hypertension: Comparison with Doppler Echocardiographic Estimates of Pulmonary Arterial Pressure
por: Visser, L.C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fsua4d5fs18704ash5v7vrq746